甲状腺相关眼病的治疗进展及生活质量研究
Progress in Treatment and Quality of Life of Thyroid-Associated Ophthalmopathy
DOI: 10.12677/ACM.2023.1381718, PDF,   
作者: 梁伊日贵：内蒙古民族大学第二临床医学院内分泌科，内蒙古 呼伦贝尔；张春香*：内蒙古林业总医院内分泌科，内蒙古 呼伦贝尔
关键词: 甲状腺相关眼病；治疗进展；生活质量；Thyroid Related Ophthalmopathy； Treatment Progress； Quality of Life
摘要: 甲状腺相关眼病(TAO)又称Graves眼病(GO)，常见于Graves病，是一种器官特异性自身免疫性疾病，是成人最常见的眼眶疾病，它会导致眼睛鼓胀、复视、视神经受压和视力丧失，对生活质量有重大影响。TAO的治疗常用糖皮质激素、放疗或手术治疗，此外，新型靶向药物逐渐被开发出来，包括teprotumumab (抗IGF-1R单克隆抗体)和rituximab (抗CD20单克隆抗体)。本文就甲状腺相关眼病治疗进展及生活质量研究进行一简要综述。
Abstract: Thyroid associated ophthalmopathy (TAO), also known as Graves’ ophthalmopathy (GO), is an or-gan-specific autoimmune disease commonly seen in Graves’ disease. It is the most common orbital disease in adults. Tao causes eye distention, double vision, optic nerve compression and vision loss, which has a significant impact on quality of life. Treatment of TAO is usually treated with glucocor-ticoids, radiotherapy or surgery, and novel targeted drugs are gradually being developed, including teprotumumab (anti-IGF-1R monoclonal antibody) and rituximab (anti-CD20 monoclonal antibody). This article reviews the progress in treatment and quality of life of thyroid related ophthalmopathy.
文章引用：梁伊日贵, 张春香. 甲状腺相关眼病的治疗进展及生活质量研究[J]. 临床医学进展, 2023, 13(8): 12264-12270. https://doi.org/10.12677/ACM.2023.1381718

参考文献

[1] Bartalena, L., Kahaly, G.J., Baldeschi, L., Dayan, C.M., Eckstein, A., Marcocci, C., et al. (2021) The 2021 European Group on Graves’ Orbitopathy (EUGOGO) Clinical Practice Guidelines for the Medical Management of Graves’ Or-bitopathy. European Journal of Endocrinology, 185, G43-G67.
[2] Ross, D.S., Burch, H.B., Cooper, D.S., Greenlee, M.C., Laurberg, P., Maia, A.L., et al. (2016) 2016 American Thyroid Association Guidelines for Diagnosis and Man-agement of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid, 26, 1343-1421. [Google Scholar] [CrossRef] [PubMed]
[3] Patel, A., Yang, H. and Douglas, R.S. (2019) A New Era in the Treat-ment of Thyroid Eye Disease. American Journal of Ophthalmology, 208, 281-288. [Google Scholar] [CrossRef] [PubMed]
[4] Cockerham, K.P., Padnick-Silver, L., Stuertz, N., Francis-Sedlak, M. and Holt, R.J. (2021) Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States. Ophthalmology and Therapy, 10, 975-987. [Google Scholar] [CrossRef] [PubMed]
[5] Wang, Y., Padnick-Silver, L., Francis-Sedlak, M., Holt, R.J., Foley, C. and Douglas, R.S. (2022) Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States. Endocrine Practice, 28, 842-846. [Google Scholar] [CrossRef] [PubMed]
[6] 税宇萍, 冯先琼, 曾继红, 等. 甲状腺相关眼病病人生活质量研究进展[J]. 护理研究, 2021, 35(2): 273-276.
[7] 王星, 叶慧菁, 杨华胜. 甲状腺相关眼病的非手术治疗现状及研究进展[J]. 国际眼科杂志, 2022, 22(8): 1288-1292.
[8] Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G.J., Marcocci, C., et al. (2016) The 2016 European Thyroid Association/European Group on Graves’ Orbitop-athy Guidelines for the Management of Graves’ Orbitopathy. European Thyroid Journal, 5, 9-26. [Google Scholar] [CrossRef] [PubMed]
[9] Douglas, R.S., Kahaly, G.J., Patel, A., Sile, S., Thompson, E.H.Z., Perdok, R., et al. (2020) Teprotumumab for the Treatment of Active Thyroid Eye Disease. The New England Journal of Medicine, 382, 341-352. [Google Scholar] [CrossRef] 
[10] Nie, T. and Lamb, Y.N. (2022) Teprotumumab: A Review in Thy-roid Eye Disease. Drugs, 82, 1663-1670. [Google Scholar] [CrossRef] [PubMed]
[11] Stan, M.N., Garrity, J.A., Carranza Leon, B.G., Prabin, T., Bradley, E.A. and Bahn, R.S. (2015) Randomized Controlled Trial of Rituximab in Patients with Graves’ Orbitopathy. The Journal of Clinical Endocrinology & Metabolism, 100, 432-441. [Google Scholar] [CrossRef] [PubMed]
[12] Salvi, M., Vannucchi, G., Currò, N., Campi, I., Covelli, D., Dazzi, D., et al. (2015) Efficacy of B-Cell Targeted Therapy with Rituximab in Patients with Active Moderate to Severe Graves’ Or-bitopathy: A Randomized Controlled Study. The Journal of Clinical Endocrinology & Metabolism, 100, 422-431. [Google Scholar] [CrossRef] [PubMed]
[13] Kahaly, G., Schrezenmeir, J., Krause, U., Schweikert, B., Meuer, S., Muller, W., et al. (1986) Ciclosporin and Prednisone v. Prednisone in Treatment of Graves’ Ophthalmopathy: A Con-trolled, Randomized and Prospective Study. European Journal of Clinical Investigation, 16, 415-422. [Google Scholar] [CrossRef] [PubMed]
[14] Prummel, M.F., Mourits, M.P., Berghout, A., Krenning, E.P., van der Gaag, R., Koornneef, L. and Wiersinga, W.M. (1989) Prednisone and Cyclosporine in the Treatment of Se-vere Graves’ Ophthalmopathy. The New England Journal of Medicine, 321, 1353-1359. [Google Scholar] [CrossRef] 
[15] Hamed Azzam, S., Kang, S., Salvi, M. and Ezra, D.G. (2018) Tocilizumab for Thyroid Eye Disease. Cochrane Database of Systematic Reviews, 11, CD012984. [Google Scholar] [CrossRef] 
[16] Allison, A.C. and Eugui, E.M. (2000) Mycophenolate Mofetil and Its Mechanisms of Action. Immunopharmacology, 47, 85-118. [Google Scholar] [CrossRef] 
[17] Ye, X., Bo, X., Hu, X., et al. (2017) Efficacy and Safety of Mycophenolate Mofetil in Patients with Active Moderate-to-Severe Graves’ Orbitopathy [Retracted in: Clin Endocrinol (Oxf). 2023 May, 98(5): 743]. Clinical Endocrinology (Oxford), 86, 247-255. [Google Scholar] [CrossRef] [PubMed]
[18] Kahaly, G.J., Riedl, M., König, J., Pitz, S., Ponto, K., Diana, T., et al. (2018) Mycophenolate plus Methylprednisolone versus Methylprednisolone Alone in Active, Moderate-to-Severe Graves’ Or-bitopathy (MINGO): A Randomised, Observer-Masked, Multicentre Trial. The Lancet Diabetes & Endocrinology, 6, 287-298. [Google Scholar] [CrossRef] 
[19] Lee, A.C.H., Riedl, M., Frommer, L., Diana, T. and Kahaly, G.J. (2020) Systemic Safety Analysis of Mycophenolate in Graves’ Orbitopathy. Journal of Endocrinological Investiga-tion, 43, 767-777. [Google Scholar] [CrossRef] [PubMed]
[20] Dolman, P.J. and Rath, S. (2012) Orbital Radiotherapy for Thy-roid Eye Disease. Current Opinion in Ophthalmology, 23, 427-432. [Google Scholar] [CrossRef] 
[21] Johnson, K.T., Wittig, A., Loesch, C., Esser, J., Sauerwein, W. and Eckstein, A.K. (2010) A Retrospective Study on the Efficacy of Total Absorbed Orbital Doses of 12, 16 and 20 Gy Combined with Systemic Steroid Treatment in Patients with Graves’ Orbitopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology, 248, 103-109. [Google Scholar] [CrossRef] [PubMed]
[22] Kahaly, G.J., Rösler, H.P., Pitz, S. and Hommel, G. (2000) Low- versus High-Dose Radiotherapy for Graves’ Ophthalmopathy: A Randomized, Single Blind Trial. The Journal of Clini-cal Endocrinology & Metabolism, 85, 102-108. [Google Scholar] [CrossRef] [PubMed]
[23] Godfrey, K.J. and Kazim, M. (2018) Radiotherapy for Active Thyroid Eye Disease. Ophthalmic Plastic & Reconstructive Surgery, 34, S98-S104. [Google Scholar] [CrossRef] 
[24] Sobel, R.K., Aakalu, V.K., Vagefi, M.R., Foster, J.A., Tao, J.P., et al. (2022) Orbital Radiation for Thyroid Eye Disease: A Report by the American Academy of Ophthalmology. Ophthalmology, 129, 450-455. [Google Scholar] [CrossRef] [PubMed]
[25] Marcocci, C., Bartalena, L., Rocchi, R., Marinò, M., Menconi, F., Morabito, E., et al. (2003) Long-Term Safety of Orbital Radiotherapy for Graves’ Ophthalmopathy. The Journal of Clin-ical Endocrinology & Metabolism, 88, 3561-3566. [Google Scholar] [CrossRef] [PubMed]
[26] Wakelkamp, I.M., Tan, H., Saeed, P., Schlingemann, R.O., Verbraak, F.D., Blank, L.E., Prummel, M.F. and Wiersinga, W.M. (2004) Orbital Irradiation for Graves’ Ophthalmopathy: Is It Safe? A Long-Term Follow-Up Study. Ophthalmology, 111, 1557-1562. [Google Scholar] [CrossRef] [PubMed]
[27] Dagi, L.R., Elliott, A.T., Roper-Hall, G. and Cruz, O.A. (2010) Thyroid Eye Disease: Honing Your Skills to Improve Outcomes. Journal of AAPOS, 14, 425-431. [Google Scholar] [CrossRef] [PubMed]
[28] Naik, M.N., Nair, A.G., Gupta, A. and Kamal, S. (2015) Mini-mally Invasive Surgery for Thyroid Eye Disease. Indian Journal of Ophthalmology, 63, 847-853. [Google Scholar] [CrossRef] [PubMed]
[29] Goh, M.S. and McNab, A.A. (2005) Orbital Decompression in Graves’ Orbitopathy: Efficacy and Safety. Internal Medicine Journal, 35, 586-591. [Google Scholar] [CrossRef] [PubMed]
[30] Schotthoefer, E.O. and Wallace, D.K. (2007) Strabismus Associated with Thyroid Eye Disease. Current Opinion in Ophthalmology, 18, 361-365. [Google Scholar] [CrossRef] 
[31] Wan, M.J. and Hunter, D.G. (2014) Complications of Stra-bismus Surgery: Incidence and Risk Factors. Seminars in Ophthalmology, 29, 421-428. [Google Scholar] [CrossRef] [PubMed]
[32] Bothun, E.D., Scheurer, R.A., Harrison, A.R. and Lee, M.S. (2009) Update on Thyroid Eye Disease and Management. Clinical Ophthalmology, 3, 543-551. [Google Scholar] [CrossRef] 
[33] Terwee, C.B., Gerding, M.N., Dekker, F.W., Prummel, M.F. and Wiersinga, W.M. (1998) Development of a Disease Specific Quality of Life Questionnaire for Patients with Graves’ Ophthalmopathy: The GO-QOL. British Journal of Ophthalmology, 82, 773-779. [Google Scholar] [CrossRef] [PubMed]
[34] Gerding, M.N., Terwee, C.B., Dekker, F.W., Koornneef, L., Prummel, M.F. and Wiersinga, W.M. (1997) Quality of Life in Patients with Graves’ Ophthalmopathy Is Markedly Decreased: Measurement by the Medical Outcomes Study Instrument. Thyroid, 7, 885-889. [Google Scholar] [CrossRef] [PubMed]
[35] Estcourt, S., Hickey, J., Perros, P., Dayan, C. and Vaidya, B. (2009) The Patient Experience of Services for Thyroid Eye Disease in the United Kingdom: Results of a Nationwide Survey. European Journal of Endocrinology, 161, 483-487. [Google Scholar] [CrossRef] 
[36] Farid, M., Roch-Levecq, A.C., Levi, L., Brody, B.L., Granet, D.B. and Kikkawa, D.O. (2005) Psychological Disturbance in Graves Ophthalmopathy. Archives of Ophthalmology, 123, 491-496. [Google Scholar] [CrossRef] [PubMed]
[37] Wang, Y., Sharma, A., Padnick-Silver, L., Francis-Sedlak, M., Holt, R.J., Foley, C., Massry, G. and Douglas, R.S. (2021) Physician-Perceived Impact of Thyroid Eye Disease on Pa-tient Quality of Life in the United States. Ophthalmology and Therapy, 10, 75-87. [Google Scholar] [CrossRef] [PubMed]
[38] Marcocci, C., Kahaly, G.J., Krassas, G.E., Bartalena, L., Prum-mel, M., Stahl, M., et al. (2011) Selenium and the Course of Mild Graves’ Orbitopathy. The New England Journal of Medicine, 364, 1920-1931. [Google Scholar] [CrossRef] 
[39] Kashkouli, M.B., Heidari, I., Pakdel, F., Jam, S., Honarbakhsh, Y. and Mirarmandehi, B. (2011) Change in Quality of Life after Medical and Surgical Treatment of Graves’ Ophthalmopa-thy. Middle East African Journal of Ophthalmology, 18, 42-47. [Google Scholar] [CrossRef] [PubMed]
[40] Terwee, C.B., Dekker, F.W., Mourits, M.P., Gerding, M.N., Baldeschi, L., Kalmann, R., et al. (2001) Interpretation and Validity of Changes in Scores on the Graves’ Ophthalmopa-thy Quality of Life Questionnaire (GO-QOL) after Different Treatments. Clinical Endocrinology (Oxford), 54, 391-398. [Google Scholar] [CrossRef] [PubMed]
[41] Yeatts, R.P. (2005) Quality of Life in Patients with Graves Ophthalmopathy. Transactions of the American Ophthalmological Society, 103, 368-411.
[42] Fayers, T. and Dolman, P.J. (2011) Validity and Reliability of the TED-QOL: A New Three-Item Questionnaire to Assess Quality of Life in Thyroid Eye Disease. British Journal of Ophthalmology, 95, 1670-1674. [Google Scholar] [CrossRef] [PubMed]

为你推荐